Trinity Capital, an alternative asset manager, committed up to $50 million in growth funding to Nalu Medical, a commercial-stage medical device company focused on developing and commercializing neurostimulation solutions for patients with chronic intractable neuropathic pain.
“We are proud to partner with and support Nalu as they advance the care of patients with chronic neuropathic pain,” Rob Lake, senior managing director of life sciences at Trinity Capital, said. “We believe Nalu is a leader in PNS and is reshaping the pain management landscape through their innovative technology and robust clinical data.”
“We welcome Trinity Capital as a financing partner and appreciate their confidence in providing us this important financial flexibility as we continue our commercial expansion of our newly launch, next-generation Therapy Disc, and build upon our recent publication of what we believe is the largest long-term real-world data set for a permanent PNS device that demonstrated reliable long-term pain relief to a broad spectrum of patients,” Tom West, president and CEO of Nalu, said.
